R&D channel feed

Mor­phoSys march­es ahead with plans to file myelofi­bro­sis drug de­spite mixed PhI­II re­sults

Last year

Flag­ship launch­es first UK-based start­up to un­cov­er genes that make cells vul­ner­a­ble or re­sis­tant to dis­ease

Last year
Financing
Startups

CAR-T cell ther­a­pies in­fused in­to brain shrink tu­mors in two glioblas­toma stud­ies

Last year
Cell/Gene Tx

'In­fe­ri­or ef­fi­ca­cy' leads to pre­ma­ture end of PhI­II for Bay­er's next-gen blood thin­ner asun­dex­i­an

Last year

Mer­ck cough drug fails to win ad­comm’s back­ing as FDA rais­es ef­fi­ca­cy ques­tions

Last year

Pfiz­er, Astel­las clinch ex­pand­ed ap­proval for Xtan­di in ear­li­er line of prostate can­cer

Last year
Pharma
FDA+

Astel­las de­tails po­ten­tial rea­son be­hind deaths in rare dis­ease gene ther­a­py tri­al

Last year
Cell/Gene Tx

Lil­ly in­vests $2.5B in new Ger­man site to boost tirzepatide sup­ply, $100M for lo­cal biotechs

Last year
Manufacturing

Q&A: Can on­colyt­ic virus­es make a come­back? Ex­perts dis­sect clin­i­cal fail­ures and out­line path for­ward

Last year

Pa­tient foun­da­tion ac­cus­es rare dis­ease com­pa­ny Taysha of vi­o­lat­ing li­cens­ing agree­ment

Last year
Cell/Gene Tx

Spring­Works eyes US fil­ing for MEK in­hibitor af­ter pos­i­tive PhI­Ib da­ta in rare dis­ease

Last year

Scoop: Rakuten Med­ical tar­gets year-end close for $100M+ Se­ries E to fund pho­toim­munother­a­py pipeline: #Jef­feries23

Last year
Financing

Gen­er­ate:Bio­med­i­cines opens the hood on its AI soft­ware for mak­ing pro­teins

Last year
AI

Verve won tri­al suc­cess with a gene-edit­ing mile­stone. Why don't in­vestors like it?

Last year
Cell/Gene Tx

As­traZeneca's con­cur­rent Imfinzi-chemo-ra­di­a­tion com­bo in lung can­cer miss­es pri­ma­ry end­point in PhI­II tri­al

Last year
Pharma

The­seus Phar­ma­ceu­ti­cals lays off most work­ers and seeks 's­trate­gic al­ter­na­tives' af­ter can­cer pipeline fail­ure

Last year
People

Ipsen, Gen­fit un­veil ad­di­tion­al PhI­II da­ta for rare liv­er dis­ease drug, fur­ther boost­ing reg­u­la­to­ry am­bi­tion

Last year

Bridge­Bio eyes US fil­ing for AT­TR-CM drug af­ter new PhI­II da­ta show ‘fastest’ clin­i­cal ben­e­fit to date

Last year

An­thos' blood thin­ner cuts the risk of bleed­ing amid race to de­vel­op safer an­ti­co­ag­u­lants

Last year

Aclaris los­es 85% of share val­ue af­ter an­oth­er PhII set­back in in­flam­ma­to­ry con­di­tion

Last year

Al­ny­lam’s longer-term RNAi treat­ment low­ers blood pres­sure in mid-stage study

Last year

First da­ta for Lil­ly's RNA treat­ment for heart dis­ease point to long-term dura­bil­i­ty in tiny group of pa­tients

Last year

Verve shares first base edit­ing re­sults in hu­mans, sug­gest­ing ther­a­py can low­er cho­les­terol in pa­tients with ge­net­ic con­di­tion

Last year

Af­ter show­ing We­govy cut car­dio­vas­cu­lar risk by 20%, re­sults de­tail im­pact on death and heart fail­ure

Last year
Pharma
First page Previous page 63646566676869 Next page Last page
A service from the Financial Times